COVID-19 vaccines and kidney disease

Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general populatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Windpessl, Martin, Bruchfeld, Annette, Anders, Hans-Joachim, Kramer, Holly, Waldman, Meryl, Renia, Laurent, Ng, Lisa F. P., Xing, Zhou, Kronbichler, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869766/
https://www.ncbi.nlm.nih.gov/pubmed/33558753
http://dx.doi.org/10.1038/s41581-021-00406-6
_version_ 1783648692341833728
author Windpessl, Martin
Bruchfeld, Annette
Anders, Hans-Joachim
Kramer, Holly
Waldman, Meryl
Renia, Laurent
Ng, Lisa F. P.
Xing, Zhou
Kronbichler, Andreas
author_facet Windpessl, Martin
Bruchfeld, Annette
Anders, Hans-Joachim
Kramer, Holly
Waldman, Meryl
Renia, Laurent
Ng, Lisa F. P.
Xing, Zhou
Kronbichler, Andreas
author_sort Windpessl, Martin
collection PubMed
description Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.
format Online
Article
Text
id pubmed-7869766
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78697662021-02-09 COVID-19 vaccines and kidney disease Windpessl, Martin Bruchfeld, Annette Anders, Hans-Joachim Kramer, Holly Waldman, Meryl Renia, Laurent Ng, Lisa F. P. Xing, Zhou Kronbichler, Andreas Nat Rev Nephrol Comment Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred. Nature Publishing Group UK 2021-02-08 2021 /pmc/articles/PMC7869766/ /pubmed/33558753 http://dx.doi.org/10.1038/s41581-021-00406-6 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Windpessl, Martin
Bruchfeld, Annette
Anders, Hans-Joachim
Kramer, Holly
Waldman, Meryl
Renia, Laurent
Ng, Lisa F. P.
Xing, Zhou
Kronbichler, Andreas
COVID-19 vaccines and kidney disease
title COVID-19 vaccines and kidney disease
title_full COVID-19 vaccines and kidney disease
title_fullStr COVID-19 vaccines and kidney disease
title_full_unstemmed COVID-19 vaccines and kidney disease
title_short COVID-19 vaccines and kidney disease
title_sort covid-19 vaccines and kidney disease
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869766/
https://www.ncbi.nlm.nih.gov/pubmed/33558753
http://dx.doi.org/10.1038/s41581-021-00406-6
work_keys_str_mv AT windpesslmartin covid19vaccinesandkidneydisease
AT bruchfeldannette covid19vaccinesandkidneydisease
AT andershansjoachim covid19vaccinesandkidneydisease
AT kramerholly covid19vaccinesandkidneydisease
AT waldmanmeryl covid19vaccinesandkidneydisease
AT renialaurent covid19vaccinesandkidneydisease
AT nglisafp covid19vaccinesandkidneydisease
AT xingzhou covid19vaccinesandkidneydisease
AT kronbichlerandreas covid19vaccinesandkidneydisease

Ejemplares similares